Tag Directory / BIOTECH     showing 1–1 of 1   RSS

for: Sunday, July 26, 2026



FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma

esmo - Evidence for efficacy is based on the results from the LITESPARK-022 study

AI Summary: Regulators have cleared the combination of belzutifan and pembrolizumab as adjuvant therapy for renal cell carcinoma at high risk of recurrence after nephrectomy. Clinical data showed improved disease‑free survival versus control, offering a new post‑surgery option intended to delay recurrence in patients with residual recurrence risk.

Metastatic Renal Cell Carcinoma in 2026: Frontline Combinations, Post-IO Sequencing, and the Emergence of HIF-2α Inhibition

22 days / oncodaily

Tian Zhang: Grateful to Share the Latest Advances in RCC at the 35th Annual Mayo Review

25 days / oncodaily

Adjuvant Therapy in Renal Cell Carcinoma: Who Benefits and Who Is Overtreated

26 days / oncodaily

Charles Jiang: Why the P-Value Is the Least Useful Number on the Slide in Adjuvant Clinical Trials

29 days / oncodaily

FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma

5 wks / esmo

Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence

5 wks / esmo



Back to Top


BIOTECH Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.


StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Neuroscience, Drug Development, Supplements, Product Recall and look for the RSS link.

Back to Top
↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.